Improvement of lower urinary tract symptoms and incidence of retrograde ejaculation when 2.5mg or 5mg of Terazosin is administered to patients with benign prostatic hyperplasia
Not Applicable
- Conditions
- Diseases of The genitoruinary system
- Registration Number
- KCT0005531
- Lead Sponsor
- Pusan National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 142
Inclusion Criteria
1) Adult male over 19 years old
2) Those with an IPSS total score of 8 or more
3) Those with a maximum urine velocity (Qmax) of less than 10mL/s
4) Those who agreed to participate in this study by handwriting
Exclusion Criteria
1) Those who are hypersensitive to a-blocker drugs
2) Those with bladder neck stenosis or urinary tract stenosis
3) Those with renal dysfunction (serum creatine concentration>2.0mg/dL)
4) Those with severe liver disorder or medical history
5) Those with severe cardiovascular disease
6) Those with severe low blood pressure
7) Others who are inadequate to participate in this research as the research director judges
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method International Prostate Symptom Score
- Secondary Outcome Measures
Name Time Method umber of patients who experience retrograde ejaculation